Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Denali Therapeutics Inc., Krystal Biotech or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Denali Therapeutics Inc., Krystal Biotech and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Denali Therapeutics Inc., Krystal Biotech and Inc.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson’s and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company’s OTV programs also comprise DNL628 targeting tau for Alzheimer’s disease; and DNL422 targeting alpha synuclein for Parkinson’s disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer’s disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Latest Biotechnology and Denali Therapeutics Inc., Krystal Biotech, Inc. Stock News

As of July 31, 2026, Denali Therapeutics Inc. had a $3.7 billion market capitalization, compared to the Biotechnology median of $252.6 million. Denali Therapeutics Inc.’s stock is up 39.4% in 2026, down 0.4% in the previous five trading days and up 68.4% in the past year.

Currently, Denali Therapeutics Inc. does not have a price-earnings ratio. Denali Therapeutics Inc.’s trailing 12-month revenue is $0.0 million with a % net profit margin. As of July 31, 2026, Denali Therapeutics Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-2.372 per share for the current fiscal year. Denali Therapeutics Inc. does not currently pay a dividend.

As of July 31, 2026, Krystal Biotech, Inc. had a $10.1 billion market cap, putting it in the 77th percentile of all stocks. Krystal Biotech, Inc.’s stock is up 38.4% in 2026, up 1.8% in the previous five trading days and up 122.63% in the past year.

Currently, Krystal Biotech, Inc.’s price-earnings ratio is 45.7. Krystal Biotech, Inc.’s trailing 12-month revenue is $417.3 million with a 53.9% net profit margin. Year-over-year quarterly sales growth most recently was 32.0%. Analysts expect adjusted earnings to reach $8.206 per share for the current fiscal year. Krystal Biotech, Inc. does not currently pay a dividend.

How We Compare Denali Therapeutics Inc., Krystal Biotech and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Denali Therapeutics Inc., Krystal Biotech and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Denali Therapeutics Inc., Krystal Biotech and Inc.’s Quality Grades

Company	Ticker	Quality
Denali Therapeutics Inc.	DNLI	F
Krystal Biotech, Inc.	KRYS	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Denali Therapeutics Inc. has a Quality Score of 6, which is Very Weak. Krystal Biotech, Inc. has a Quality Score of 81, which is Very Strong.

The Quality Grade Winner: Krystal Biotech, Inc.

As you can clearly see from the Quality Grade breakdown above, Krystal Biotech, Inc. has a better overall quality grade than Denali Therapeutics Inc.. For investors who are looking for companies with higher quality than others in the same industry, Krystal Biotech, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Denali Therapeutics Inc., Krystal Biotech and Inc.’s Momentum Grades

Company	Ticker	Momentum
Denali Therapeutics Inc.	DNLI	A
Krystal Biotech, Inc.	KRYS	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Denali Therapeutics Inc. has a Momentum Score of 86, which is Very Strong. Krystal Biotech, Inc. has a Momentum Score of 92, which is Very Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both Denali Therapeutics Inc., Krystal Biotech and Inc. have a grade of A. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

Denali Therapeutics Inc., Krystal Biotech and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Denali Therapeutics Inc.	DNLI	D
Krystal Biotech, Inc.	KRYS	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Denali Therapeutics Inc. has a Earnings Estimate Score of 40, which is Negative. Krystal Biotech, Inc. has a Earnings Estimate Score of 52, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Denali Therapeutics Inc., Krystal Biotech or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Denali Therapeutics Inc., Krystal Biotech or Inc. is the better investment when it comes to estimate revisions.

Other Denali Therapeutics Inc., Krystal Biotech and Inc. Grades

In addition to Quality, Estimate Revisions and Momentum, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Denali Therapeutics Inc., Krystal Biotech and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Denali Therapeutics Inc., Krystal Biotech or Inc. Stock?

Overall, Denali Therapeutics Inc. stock has a Momentum Score of 86, Estimate Revisions Score of 40 and Quality Score of 6.

Krystal Biotech, Inc. stock has a Momentum Score of 92, Estimate Revisions Score of 52 and Quality Score of 81.

Comparing Denali Therapeutics Inc., Krystal Biotech and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.